ALK and non-small cell lung carcinoma: For example, non-small-cell lung cancers (NSCLC) harboring gain-of-function mutations in the epidermal growth factor receptor (EGFR) gene or anaplastic lymphoma kinase (ALK) genes are now likely to be treated with first-line tyrosine kinase inhibitors [38].